DelveInsight’s, “Nontuberculous mycobacterial (NTM) Infections-Pipeline Insight, 2020,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Nontuberculous mycobacterial Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Nontuberculous mycobacterial Infections: Overview
Nontuberculous mycobacterial (NTM) lung disease is a general term for a group of disorders characterized by exposure to specific bacterial germs known as mycobacteria. These germs are found in the water and soil and are common throughout the environment as a whole. They usually do not cause illness. The term ‘nontuberculous’ is used to differentiate these disorders from the mycobacterium that cause tuberculosis (i.e. mycobacterium tuberculosis complex).
The symptoms and severity can vary greatly from one person to another. The reason for this variability is not fully understood. Chronic lung infection is the most common complication affecting approximately 94% of individuals. The symptoms are usually nonspecific and similar to the symptoms seen in other lung or respiratory infections. Such symptoms include cough, fatigue, shortness of breath (dyspnea), coughing up of blood (hemoptysis), excessive mucus (sputum) production, fever, night sweats, loss of appetite, and unintended weight loss. Wheezing and chest pain may also occur. Affected individuals may experience recurrent respiratory infections. In some cases, these infections can cause progressive damage to the lungs and, eventually, the lungs will not function as well as they should (impaired lung function).
A diagnosis of nontuberculous mycobacterial lung disease is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. However, the diagnosis can be challenging because the characteristic signs and symptoms are highly variable and nonspecific. A diagnosis of NTM includes ruling out other diseases such as tuberculosis or lung cancer.
Treatment with a combination of antibiotic drugs (drug regimen) is the mainstay of therapy for these diseases. However, these drugs carry certain risks (side effects) and are often poorly tolerated, have a high cost, and require individuals to remain on the medications for a lengthy period of time. These risks must be weighed against the potential benefits for each individual based upon the severity of their disease and specific symptoms that are present. If a decision is made not to treat, then an affected individual should be closely monitored to promptly detect any progression of the infection.
This segment of the Nontuberculous mycobacterial Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Molgradex is an inhaled formulation of recombinant human GM-CSF. The benefit of GM-CSF is that it is not an antibiotic, as many bacterial species are becoming resistant to antibiotics it stimulates the human immune system without targeting the bacteria directly, which bypasses the problem of antibiotic resistance. It is in phase II trials for treating NTM infections along with NTM in cystic fibrosis. The company awaits the trial results from both of these studies.
RHB-204 is a combination antibiotic therapy in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. If it gets approval then, may be used as a first line of treatment for Pulmonary NTM infections caused by MAC. RedHill is planning, subject to regulatory approvals, to initiate a pivotal Phase 3 study with RHB-204 for a first-line, stand-alone treatment of pulmonary NTM infections caused by Mycobacterium avium Complex (MAC).
CYT107 is a therapeutic form of the master growth factor for human T cells: Interleukin-7 (IL-7). CYT107 has been administered to over 440 patients in clinical trials and is known to substantially increase the number and diversity of T cells, including in patients in the ICU with low and exhausted T cell levels from overwhelming infections. CYT107 has an excellent safety profile, even in very sick patients.
Further product details are provided in the report……..
Nontuberculous mycobacterial Infections: Therapeutic Assessment
This segment of the report provides insights about the different Nontuberculous mycobacterial Infections drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 15+ key companies which are developing the therapies for Nontuberculous mycobacterial Infections. The companies which have their Nontuberculous mycobacterial Infections drug candidates in the most advanced stage, i.e. phase II include, Savara Pharma, Red Hill BioPharma, RevImmune.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Nontuberculous mycobacterial Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nontuberculous mycobacterial Infections therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nontuberculous mycobacterial Infections drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Nontuberculous mycobacterial Infections: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Nontuberculous mycobacterial Infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Nontuberculous mycobacterial Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nontuberculous mycobacterial Infections Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
• Comparative Analysis
Molgradex: Savara Pharma
• Product Description
• Research and Development
• Product Development Activities
RHB 204: RedHill Biopharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
SPR 720: Spero Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
CRS400226: Crestone
• Product Description
• Research and Development
• Product Development Activities
QRM-003: Qrumpharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Nontuberculous mycobacterial Infections Key Companies
Nontuberculous mycobacterial Infections Key Products
Nontuberculous mycobacterial Infections- Unmet Needs
Nontuberculous mycobacterial Infections- Market Drivers and Barriers
Nontuberculous mycobacterial Infections- Future Perspectives and Conclusion
Nontuberculous mycobacterial Infections Analyst Views
Nontuberculous mycobacterial Infections Key Companies
Appendix
List of Tables
Table 1 Total Products for Nontuberculous mycobacterial Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Nontuberculous mycobacterial Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
• Savara Pharma
• Red Hill BioPharma
• RevImmune
• Mallinckrodt
• Insmed Incorporated
• Novoteris
• Beyond Air
• Spero Therapeutics
• Crestone
• Qrumpharma
